Bristol-Myers Squibb Company
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christopher S. Boerner
- Full Time Employees
- 34,100
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Route 206 & Province Line Road Princeton NJ United States of America 08543
- IPO Date
- Jun 1, 1972
- CIK
- 0000014272
- Website
- bms.com
- Similar Companies
- Business
- Bristol-Myers Squibb Company (NYSE: BMY), a global biopharmaceutical company headquartered in Princeton, New Jersey with roots tracing to mergers of entities founded in 1858 and 1887, discovers, develops, manufactures, and commercializes innovative medicines for serious diseases including cancer, immunology, cardiovascular, hematology, and neuroscience disorders; its primary products include the anticoagulant Eliquis (apixaban), oncology therapies such as Opdivo (nivolumab), Yervoy, Krazati, and Revlimid (lenalidomide), cell therapies Abecma and Breyanzi, immunomodulators like Orencia and Pomalyst, legacy brands such as Abraxane, Camzyos for hypertrophic cardiomyopathy, Cobenfy in neuroscience, and others including Baraclude, IDHIFA, Inrebic, Nulojix, Opdivo Qvantig, Reblozyl, and Thalidomid; the company operates in more than 120 countries with a focus on oncology, hematology, immunology, cardiovascular, and fibrotic diseases targeting patients with high unmet needs. In recent developments, Bristol-Myers Squibb completes the acquisition of Orbital Therapeutics in 2025 to strengthen its cell therapy portfolio with RNA medicines reprogramming the immune system; it forms a joint venture with Bain Capital in July 2025 for innovative immunology therapies and enters a global strategic partnership with BioNTech in June 2025 to co-develop and co-commercialize next-generation bispecific antibody BNT327 for multiple solid tumors; earlier, the company acquires 2seventy bio in March 2025 for full control of Abecma amid competitive pressures, completes acquisitions of Karuna Therapeutics in March 2024 to bolster neuroscience, RayzeBio in February 2024 for actinium-based radiopharmaceuticals, and Mirati Therapeutics in January 2024 to diversify oncology, alongside a $380 million capacity agreement with Cellares in April 2024 for CAR T manufacturing.
Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know
Billionaire Izzy Englander Just Made a Big Bet on This Beaten-Down High-Yield Dividend Stock
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer?
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer
Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now?
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?
BMY Gets Opdivo Label Expansion in the EU, Update on Camzyos
Bristol Myers Squibb: This Pullback Is A Gift For Long-Term Investors
Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma
Bristol Myers' Growth Portfolio Just Overtook The Legacy One
Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks
Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
Globale Daten der ROSETTA Lung-02-Studie: Ermutigende Wirksamkeit für BioNTechs und Bristol Myers Squibbs bispezifischen PD-L1xVEGF-A-Immunmodulator-Kandidat Pumitamig bei nicht-kleinzelligem Lungenkrebs